DEC 19, 2017 11:11 AM PST

Resolution of the D4 Dopamine Receptor for Drug Discovery

Dopamine receptors are a class of G-protein-couple receptors which span cell membranes to facilitate signal transduction and multiple functions of the cell. G-protein coupled receptors, or GPCRs, also represent a class of highly targeted receptors therapeutically and dopamine receptors are most definitely included in this grouping. Dopamine receptors in specific are an essential part of the central nervous system where they act to facilitate neurotransmission and neuroendocrine signaling. They are integral to many neurological processes such as learning, motor skills, cognition, memory, etc., and alterations in their signaling or function underlies almost every neuropsychiatric disorder. This makes them ideal therapeutic targets in these types of disease. Recently a collaborative group out of Stanford University, California, the University of California, San Francisco, and the University of North Carolina, Chapel Hill, have determined the crystal structure of the D4 dopamine receptor family member. Why is this a good thing? According to this group, “the ability to efficiently exploit structure for specific probe discovery – rapidly moving from elucidating receptor structure to discovering previously unrecognized, selective agonists – testifies to the power of structure based approaches.” This crystal structure also provides a basis by which new therapeutic compounds can be virtually screened to test for binding to the structure, and if any are found to be promising leads, they can be followed up biologically.

Dopamine receptors are implicated in schizophrenia, drug abuse, and Parkinson’s disease to name a few, so identifying new molecules and compounds to combat any or all of them represents much needed progress forward in the field. There are currently many compounds thought to target dopamine receptors, and in specific the D4 family member, but the specificity of these drugs may be less than optimal and the molecular mechanisms underlying is not fully understood. Finding new agonists would not only potentially provide more selective modalities, but would also help us to better understand the biology. In the study mentioned above, the researchers were able to crystalize D4 dopamine receptor in an inactive state while bound to the antipsychotic drug nemonapride with high resolution. This data was then used for computational ligand discovery coupled with biological/pharmacological assays to verify novel, previously unrecognized probes with high selectivity and potency toward this receptor. This has provided the ground work for new therapeutic opportunities in treating a wide range of neuropsychiatric disorders.

Sources: Wikipedia, Science Magazine, Pixabay

About the Author
You May Also Like
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Does Adderall Really Work for People without ADHD?
Adderall is a popular stimulant. Known to treat Attention Deficit Disorder (ADHD), those without the condition also use it to increase attention, focus and...
NOV 20, 2019
Cancer
NOV 20, 2019
An alternative for immunotherapy-resistant cancer patients
A twist to traditional immunotherapies could help cancer patients’ immune systems better detect cancer cells, making this new system capable of targe...
NOV 20, 2019
Cancer
NOV 20, 2019
Using senolytics to treat cancer
New research published in Nature Metabolism proposes using an already existing drug – a cardiac glycoside called ouabain – as a senolytic to ki...
NOV 20, 2019
Microbiology
NOV 20, 2019
Antibody Discovered That May be the Key to a Universal Flu Vaccine
Instead of designing a new flu vaccine every year, researchers have made a breakthrough that may lead to a single vaccine that protects against all strains....
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Gene Variant Could Be a Therapeutic Target For Alzheimer Disease
A variation in genetics for an individual at high-risk for Alzheimer development has defied the odds for being dementia-free way beyond anticipated. The in...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Experimental Cholesterol-Lowering Drug
A recent study shows that patients who take a maximum dose of statin drugs in addition to a twice-yearly injection of the experimental cholesterol-lowering...
Loading Comments...